Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Executive SummarySunnyvale, California-based manufacturer of cardiovascular and surgical laser products anticipates net proceeds of $6.7 mil. from an offering of 1.7 mil. units at a price of $5 per unit, according to a registration statement filed with the Securities and Exchange Commission. The units are comprised of one share of common stock and one class A warrant. The offering is underwritten by Westfield Financial. Eclipse projects that it will use proceeds to fund repayment of notes payable and bridge notes (about $1.9 mil. combined), as well as for the marketing of approved products ($900,000) and the development and expansion of product lines in the cardiovascular, orthopedic, urology, endo-sinus surgery, and spinal surgery markets.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.